N,N-Dimethyltryptamine (DMT): Clinical Findings, Biological Foundations, and the Rebirth of Psychedelic Science

Back to: Psychedelics, Entheogens, and Consciousness Expansion

N,N-Dimethyltryptamine (DMT)

Clinical Findings, Biological Foundations, and the Rebirth of Psychedelic Science

 

You’ve probably heard a version of the story. A friend describes twenty seconds that felt like an hour. Someone on a forum writes about meeting a presence on the other side of a single inhaled breath, and insists it felt more real than the room they were sitting in. For twenty years, mainstream science had almost nothing to say about experiences like this. Not because they weren’t happening. Because the research had been shut down.

This module is about the molecule at the center of those stories: N,N-dimethyltryptamine, known simply as DMT. It’s a good place to start the deeper work of this course, because DMT sits exactly where I want us to spend our time together: the place where hard science and direct experience of something larger stop arguing with each other and start comparing notes.

I’ll say up front what I say to everyone who studies this material with me. We’re going to look at what’s been measured, documented, and published. We’re also going to look honestly at what hasn’t been proven yet, no matter how compelling it sounds. Both halves matter. The truth doesn’t need help from exaggeration.

Between 1950 and 1965, psychedelic research was mainstream psychiatry, not a fringe pursuit. Over a thousand papers were published, involving roughly 40,000 patients, exploring treatments for alcoholism, depression, and the anxiety that comes with facing death. Then the culture around these substances shifted. Psychedelics became tied to the anti-war counterculture, and in 1970 the Controlled Substances Act effectively ended sanctioned human research in the United States for two decades.

I think about that twenty-year silence often. Anyone who has spent real time in disciplined practice, military or otherwise, knows that the hardest work isn’t the breakthrough moment. It’s the slow, unglamorous rebuilding that happens after everything gets shut down. That’s exactly what happened here. No single event reopened the field. It was patient, deliberate institution building: the Multidisciplinary Association for Psychedelic Studies, founded in 1986, and the Heffter Research Institute, founded in 1993, both worked for years to rebuild scientific credibility and navigate a regulatory system that had every reason to say no.

That groundwork paid off in 1990, when Dr. Rick Strassman began his DMT studies at the University of New Mexico. They were the first FDA and DEA approved human hallucinogen trials in the United States in more than two decades. Strassman would go on to supervise over four hundred DMT sessions with sixty volunteers over five years. What he found changed the conversation permanently, and we’re still working through the implications today.

DMT is not simply a weaker or stronger version of LSD or psilocybin. It behaves differently in the body, and that difference is worth understanding before we get to the more mysterious parts of this material.

It moves fast. When administered intravenously, DMT is what researchers call ultra-short-acting. Peak blood levels and psychological effects arrive within two minutes. The entire experience resolves within thirty minutes. Compare that to psilocybin, which can take six to eight hours to run its course, and you start to understand why DMT earned the nickname “the businessman’s trip” decades before Strassman ever picked up a syringe.

It doesn’t build tolerance. This is one of the more genuinely strange findings in the pharmacology of psychedelics. Most classic hallucinogens require days of abstinence between doses to maintain their effect. DMT doesn’t play by that rule. In Strassman’s studies, subjects given four high doses in quick succession reported subjective effects that didn’t diminish. Something about how this molecule interacts with the brain sidesteps the tolerance mechanism entirely, and researchers still don’t have a complete explanation for why.

It moves the body hard, in a short window. DMT produces rapid, dose-dependent physiological changes. They’re generally safe, but they’re significant, and anyone considering this work, in a clinical or ceremonial setting, should understand them clearly.

Metric Type	Observed Effects
Cardiovascular	Spikes in blood pressure and heart rate.
Autonomic	Increased pupil diameter and rectal core temperature.
Neuroendocrine	Elevated beta-endorphin, corticotropin (ACTH), cortisol, and prolactin.
Growth Hormone	Elevated across all active doses tested.

Strassman used a tool called the Hallucinogen Rating Scale to quantify what his subjects experienced. What he found is that DMT doesn’t produce one uniform “high.” It acts, in his words, as a mind-manifester: it reveals whatever the mind is prepared to show it. Two people receiving an identical dose can walk through entirely different territory.

The Entity Encounter Phenomenon

Here’s the finding that made the field sit up and pay attention. Approximately half of Strassman’s sixty volunteers reported vivid, highly convincing encounters with intelligent, autonomous presences. Not visions of beings. Encounters with them. Participants described them as aliens, guides, angels, or spirits, using whatever language their own background gave them to reach for.

What sets this apart from what the literature calls the mystical unitive state, the classic dissolving of the self into a boundless oneness, is that DMT encounters were typically relational. The person having the experience stayed a person. They remained aware of themselves as an individual, interacting with another intelligence rather than merging into everything. Only one of Strassman’s fifty-five normal volunteers had the classic unitive experience most people associate with “ego death.” The DMT state, more often than not, keeps two parties in the room.

I don’t think it’s an accident that cultures across history, with no contact with each other, describe strikingly similar visitors: guides, spirits, luminous beings who arrive at moments of crisis or transition. Ancient wisdom traditions have been describing this territory for thousands of years, in the language available to them. Modern pharmacology just found a reliable door into the same room. That doesn’t prove what’s on the other side of the door. It does mean the question deserves more curiosity than it’s been given.

Set, Setting, and the Weight of a Life

The content of a DMT session draws heavily on the individual having it: their memories, fears, expectations, and the environment they’re in when the molecule takes hold. Many participants described their sessions as among the most meaningful experiences of their lives. Others met real fear. The emotional range ran from profound euphoria to genuine terror, and the deciding factor was rarely the dose. It was the person, and the container they were held in.

What I’ve found after years of sitting with material like this, in my own practice and in conversation with others walking a similar path, is that the container matters as much as the compound. That’s not a comforting platitude. It’s the plainest possible reading of Strassman’s own data.

Here’s where I want to slow down and be precise, because this is exactly the kind of territory where enthusiasm tends to outrun evidence.

What’s established. DMT is an endogenous compound. That means the human body manufactures it on its own. It has been detected in human blood, brain tissue, spinal fluid, and urine. This is not speculation. It’s measured fact.

What’s proposed. Strassman’s “Spirit Molecule” hypothesis suggests that the pineal gland, long regarded across cultures as a spiritual center and once described by Descartes as the seat of the soul, is the biological site where DMT is synthesized and released. The hypothesis goes further, proposing that the brain releases significant bursts of DMT during birth, death, and near-death experiences, and that spontaneous or accidental releases might explain reports of alien abduction experiences or the deepest states of meditation and sexual transcendence.

What’s honest. That second paragraph is theory, not established science. Strassman himself has said plainly that “the data aren’t there yet.” Direct biological evidence of a DMT surge in a living human brain during birth, death, or a near-death experience is extraordinarily difficult to obtain, for reasons that should be obvious. The pineal gland hypothesis is compelling. It also remains unproven.

I want to be direct with you about why this distinction matters to me. My own work is built on decades of study in consciousness, the Hermetic principles, and the places where ancient wisdom and modern science are, increasingly, saying the same thing. It would be easy, and tempting, to treat every intriguing hypothesis in this field as confirmed truth because it fits a worldview I already hold. I’d rather hand you something you can trust completely, even where that means saying “we don’t know yet.” A framework built on honest uncertainty will outlast one built on wishful certainty every time.

The most exciting recent developments in DMT research have little to do with entities or the pineal gland, and everything to do with the brain’s capacity to heal.

Early laboratory studies suggest DMT may have a neuroprotective effect on neurons damaged by ischemia, the lack of oxygen that occurs during a stroke. That finding has opened a genuine line of research into DMT, or DMT-based compounds, as a future stroke treatment, working on a completely different mechanism than the psychedelic experience itself.

The mental health research has moved fastest, and the numbers are worth sitting with. A 2022 study out of Yale examined the dose-related safety and efficacy of DMT in both healthy volunteers and people with major depressive disorder, part of the broader wave of institutional research that Strassman’s work made possible. Since then, two 2025 clinical trials have pushed the picture further. A phase 2a trial using inhaled, vaporized DMT in patients with treatment-resistant depression found a mean reduction of twenty-one points on the standard depression rating scale within seven days, with the majority of participants showing a clinically meaningful response and more than half reaching full remission, effects that held up at the three-month mark. A separate, larger, placebo-controlled trial using intravenous DMT found a statistically significant reduction in depressive symptoms compared to placebo at two weeks, with benefits that, for many participants, lasted up to three months.

None of this proves DMT is a cure for depression. Larger, longer trials are still needed, and the researchers behind this work say so themselves. What it does show is a serotonergic compound, active in the human body for less than half an hour, producing antidepressant effects that rival or exceed treatments people take every day for months. That’s not a small thing. That’s the kind of finding that reshapes a field.

Here’s what I want you to carry out of this module. DMT is not a curiosity. It’s not a party favor, and it’s not a shortcut. It’s a molecule the human body already makes, doing something in the brain that science is only beginning to map, and doing it in a way that keeps producing results too consistent to dismiss and too honest to oversell.

The entity encounters, the pineal gland hypothesis, the antidepressant data: these aren’t separate stories. They’re different instruments in the same orchestra, each one pointing toward a truth that both the mystics and the researchers have been circling for a long time. Consciousness is not simply something the brain produces and contains. Something in us, and maybe something beyond us, is a great deal larger than the models we’ve been using to describe it.

You don’t need to take my word for any of this. That’s not how this work should land on you. Read the studies. Sit with the questions. Notice where your own experience, whatever it’s been, lines up with what the data shows, and where it doesn’t. That’s the whole practice.

Welcome home to Module One. There’s a great deal more ahead.

• Strassman, R. DMT: The Spirit Molecule: A Doctor’s Revolutionary Research into the Biology of Near-Death and Mystical Experiences. Park Street Press, 2001.

• D’Souza, D.C. et al. “Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.” Neuropsychopharmacology 47, 1854 to 1862 (2022).

• Falchi-Carvalho, M. et al. “Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.” Neuropsychopharmacology 50, 895 to 903 (2025).

• James, E. et al. “A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.” Nature Medicine (2025).

• Multidisciplinary Association for Psychedelic Studies (MAPS). Organizational history. maps.org.

• Heffter Research Institute. Organizational history. heffter.org.